Your browser doesn't support javascript.
loading
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Rawstron, A C; Fazi, C; Agathangelidis, A; Villamor, N; Letestu, R; Nomdedeu, J; Palacio, C; Stehlikova, O; Kreuzer, K-A; Liptrot, S; O'Brien, D; de Tute, R M; Marinov, I; Hauwel, M; Spacek, M; Dobber, J; Kater, A P; Gambell, P; Soosapilla, A; Lozanski, G; Brachtl, G; Lin, K; Boysen, J; Hanson, C; Jorgensen, J L; Stetler-Stevenson, M; Yuan, C; Broome, H E; Rassenti, L; Craig, F; Delgado, J; Moreno, C; Bosch, F; Egle, A; Doubek, M; Pospisilova, S; Mulligan, S; Westerman, D; Sanders, C M; Emerson, R; Robins, H S; Kirsch, I; Shanafelt, T; Pettitt, A; Kipps, T J; Wierda, W G; Cymbalista, F; Hallek, M; Hillmen, P; Montserrat, E.
Affiliation
  • Rawstron AC; HMDS, St James's Institute of Oncology, Leeds, UK.
  • Fazi C; IRCCS San Raffaele Scientific Institute, Milano, Italy.
  • Agathangelidis A; IRCCS San Raffaele Scientific Institute, Milano, Italy.
  • Villamor N; Hospital Clínic, IDIBAPS, Barcelona, Spain.
  • Letestu R; Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
  • Nomdedeu J; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Palacio C; Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Stehlikova O; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
  • Kreuzer KA; University Hospital, Cologne, Germany.
  • Liptrot S; St James Hospital, Dublin, Ireland.
  • O'Brien D; St James Hospital, Dublin, Ireland.
  • de Tute RM; HMDS, St James's Institute of Oncology, Leeds, UK.
  • Marinov I; Institute of Hematology and Blood Transfusion, University Hospital Prague, Prague, Czech Republic.
  • Hauwel M; University Hospital Geneva, Geneva, Switzerland.
  • Spacek M; General University Hospital, Prague, Czech Republic.
  • Dobber J; Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.
  • Kater AP; Department of Hematology, Academic Medical Centre, Amsterdam, Netherlands.
  • Gambell P; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Soosapilla A; Hematology and Flow Cytometry, Laverty Pathology, Sydney, Australia.
  • Lozanski G; Ohio State University Medical Center, Columbus, OH, USA.
  • Brachtl G; 3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.
  • Lin K; Experimental and Clinical Cell Therapy Institute, Spinal Cord and Tissue Regeneration Center, Paracelsus Medical University, Salzburg, Austria.
  • Boysen J; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
  • Hanson C; Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
  • Jorgensen JL; Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
  • Stetler-Stevenson M; MD Anderson Cancer Center, Houston, TX, USA.
  • Yuan C; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Broome HE; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Rassenti L; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
  • Craig F; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
  • Delgado J; Un1iversity of Pittsburgh, Pittsburgh, PA, USA.
  • Moreno C; Hospital Clínic, IDIBAPS, Barcelona, Spain.
  • Bosch F; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Egle A; Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Doubek M; 3rd Medical Department, Paracelsus Medical University, Salzburg, Austria.
  • Pospisilova S; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
  • Mulligan S; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and CEITEC, Masaryk University, Brno, Czech Republic.
  • Westerman D; Department of Haematology, Royal North Shore Hospital, Sydney, Australia.
  • Sanders CM; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Emerson R; Adaptive Biotechnologies, Seattle, WA, USA.
  • Robins HS; Adaptive Biotechnologies, Seattle, WA, USA.
  • Kirsch I; Adaptive Biotechnologies, Seattle, WA, USA.
  • Shanafelt T; Adaptive Biotechnologies, Seattle, WA, USA.
  • Pettitt A; Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA.
  • Kipps TJ; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
  • Wierda WG; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
  • Cymbalista F; MD Anderson Cancer Center, Houston, TX, USA.
  • Hallek M; Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
  • Hillmen P; University Hospital, Cologne, Germany.
  • Montserrat E; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Leukemia ; 30(4): 929-36, 2016 Apr.
Article in En | MEDLINE | ID: mdl-26639181

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antigens, CD / Neoplasm, Residual / High-Throughput Nucleotide Sequencing / Flow Cytometry Type of study: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Leukemia Year: 2016 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antigens, CD / Neoplasm, Residual / High-Throughput Nucleotide Sequencing / Flow Cytometry Type of study: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Leukemia Year: 2016 Document type: Article